Weber Sabine, Wei Xinyi, Chen Guixia, Yankouskaya Katharina, Yin Decheng, Allabauer Ida, Jobst-Schwan Tilman, Wiesener Michael, Schiffer Mario, Dudziak Diana, Lehmann Christian H K, Woelfle Joachim, Hoerning André
Pediatric Gastroenterology and Hepatology, Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany.
Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Clin Exp Immunol. 2025 Jan 21;219(1). doi: 10.1093/cei/uxaf026.
mTOR inhibitor therapy is solely monitored via pharmacokinetics after kidney transplantation, which may not accurately reflect the effectiveness of PI3K-Akt-mTOR pathway blockade, potentially leading to inadequate or excessive immunosuppression. The pharmacodynamic effect of mTOR inhibition on natural killer (NK) cells and dendritic cell (DC) subsets after renal transplantation has not been investigated so far.
Phosphoflow cytometry was employed in this cross-sectional study to evaluate the extent of mTOR inhibition in peripheral DC and NK cell subsets by assessing p70S6 kinase phosphorylation in kidney transplant recipients treated with mTOR inhibitors either in combination with calcineurin inhibitors (mTORi + CNI, n = 17) or mycophenolate sodium (mTORi + MPA, n = 9). The control group comprised nine end-stage renal disease patients undergoing dialysis therapy and 17 healthy volunteers.
mTOR inhibitor-based therapy significantly reduced p70S6K phosphorylation levels in CD3-CD56+ NK cells compared to healthy controls, while p70S6K phosphorylation among HLA-DR+ Lin- total DCs was not different. In comparison to mTORi + MPA therapy, renal transplant patients receiving mTORi + CNI treatment exhibited a stronger inhibition of p70S6K phosphorylation in HLA-DR+ Lin- total DCs, CD123+CD11c- plasmacytoid DCs, CD123-CD11c+ myeloid DCs, and CD16-CD56bright NK cells. However, the serum trough levels of mTORi showed no correlation with p70S6K phosphorylation levels in all investigated cell subsets.
mTORi selectively suppressed p70S6K phosphorylation in specific DC and NK subtypes. Evaluating p70S6K phosphorylation through phosphoflow cytometry might serve as a clinically applicable method to comprehend immune cell subset-specific effects of mTOR inhibition, providing detailed pharmacodynamic insights for tailoring mTORi therapy on an individual basis.
肾移植后mTOR抑制剂治疗仅通过药代动力学进行监测,这可能无法准确反映PI3K-Akt-mTOR通路阻断的有效性,可能导致免疫抑制不足或过度。迄今为止,尚未研究肾移植后mTOR抑制对自然杀伤(NK)细胞和树突状细胞(DC)亚群的药效学作用。
在这项横断面研究中,采用磷酸化流式细胞术,通过评估接受mTOR抑制剂联合钙调神经磷酸酶抑制剂(mTORi+CNI,n=17)或麦考酚钠(mTORi+MPA,n=9)治疗的肾移植受者外周DC和NK细胞亚群中p70S6激酶的磷酸化程度,来评估mTOR抑制程度。对照组包括9例接受透析治疗的终末期肾病患者和17名健康志愿者。
与健康对照相比,基于mTOR抑制剂的治疗显著降低了CD3-CD56+NK细胞中p70S6K的磷酸化水平,而HLA-DR+Lin-总DCs中的p70S6K磷酸化没有差异。与mTORi+MPA治疗相比,接受mTORi+CNI治疗的肾移植患者在HLA-DR+Lin-总DCs、CD123+CD11c-浆细胞样DCs、CD123-CD11c+髓样DCs和CD16-CD56bright NK细胞中对p70S6K磷酸化的抑制作用更强。然而,mTORi的血清谷浓度与所有研究细胞亚群中的p70S6K磷酸化水平均无相关性。
mTORi选择性抑制特定DC和NK亚型中p70S6K的磷酸化。通过磷酸化流式细胞术评估p70S6K磷酸化可能是一种临床适用的方法,用于了解mTOR抑制对免疫细胞亚群的特异性作用,为个体化调整mTORi治疗提供详细的药效学见解。